Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Table 2 Univariate Cox regression analysis of BCR-free survival for 5mC, 5hmC, 5fC, and 5caC score

Variable	Full PC patient set			ERG- PC patient subset			ERG+ PC patient set
Variable	HR (95% CI)	p value	C-index	HR (95% CI)	p value	C-index	HR (95% CI)	p value	C-index
5mC score (cont.)	1.04 (0.72–1.50)	0.834	0.51	1.26 (0.69–2.28)	0.454	0.54	0.88 (0.54–1.43)	0.599	0.52
5mC score (dich.)	1.18 (0.85–1.62)	0.318	0.53	1.23 (0.76–2.00)	0.401	0.54	1.08 (0.70–1.69)	0.723	0.51
5hmC score (cont.)	1.37 (1.01–1.87)	0.045	0.55	1.62 (1.02–2.57)	0.043	0.59	1.14 (0.75–1.75)	0.537	0.51
5hmC score (dich.)	1.40 (1.02–1.92)	0.038	0.55	1.93 (1.19–3.14)	0.008	0.60	1.05 (0.69–1.61)	0.805	0.50
5fC score (cont.)	0.94 (0.73–1.20)	0.613	0.51	1.10 (0.78–1.56)	0.583	0.53	0.75 (0.52–1.09)	0.130	0.55
5fC score (dich.)	1.02 (0.67–1.56)	0.926	0.50	1.38 (0.77–2.49)	0.282	0.54	0.67 (0.34–1.33)	0.253	0.53
5caC score (cont.)	0.91 (0.73–1.14)	0.419	0.53	1.21 (0.86–1.71)	0.277	0.54	0.68 (0.51–0.92)	0.011	0.60
5caC score (dich.)	1.01 (0.73–1.40)	0.966	0.49	1.61 (0.98–2.63)	0.058	0.56	0.62 (0.40–0.97)	0.034	0.57

ISSN: 1868-7083